In Singapore, combination products are registered through the Health Sciences Authority (HSA). Applicants must determine the primary mode of action to classify the product as a drug, device, or biologic. The appropriate regulatory framework is then followed, involving submission of relevant documentation, safety, and efficacy data for evaluation and approval.